Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
NCT ID: NCT06939777
Last Updated: 2025-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
255 participants
INTERVENTIONAL
2025-04-30
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
NCT05625477
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
NCT06123663
To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
NCT02361866
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
NCT05832073
Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .
NCT03971370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the phase I portion of the study, 30 adult participants will be sequentially enrolled into three cohorts. Each participant will receive a single intramuscular (IM) dose of either SNA02-48 or placebo, depending on the cohort to which they are assigned. The phase I part will last for 105 days following the assessments of safety, PK, PD and ADA.
In the phase II portion of the study, 225 adult participants will be enrolled and randomly assigned to nine groups.The phase II part will last for 105 days following the assessments of safety, PK, PD and ADA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1:low-dose SNA02-48/placebo (Phase I)
Participants will be randomly assigned to receive either low-dose SNA02-48 or placebo.
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Cohort 2: medium-dose SNA02-48/placebo (Phase I)
Participants will be randomly assigned to receive either medium-dose SNA02-48 or placebo.
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Cohort 3: high-dose SNA02-48/placebo (Phase I)
Participants will be randomly assigned to receive either high-dose SNA02-48 or placebo.
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Group A :low-dose SNA02-48 + placebo (Phase II)
Participants will receive a single intramuscular (IM) gluteal injection of low-dose SNA02-48 and a single IM deltoid injection of placebo
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Group B : medium-dose SNA02-48 + placebo (Phase II)
Participants will receive a single IM gluteal injection of medium-dose SNA02-48 and a single IM deltoid injection of placebo
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Group C : high-dose SNA02-48 + placebo (Phase II)
Participants will receive a single IM gluteal injection of high-dose SNA02-48 and a single IM deltoid injection of placebo
SNA02-48
intramuscular injection
Placebo
intramuscular injection
Group D : low-dose SNA02-48 + Tetanus Toxoid (Phase II)
Participants will receive a single IM gluteal injection of low-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT）
SNA02-48
intramuscular injection
Tetanus Toxoid
intramuscular injection
Group E : medium-dose SNA02-48 + Tetanus Toxoid (Phase II)
Participants will receive a single IM gluteal injection of medium-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT）
SNA02-48
intramuscular injection
Tetanus Toxoid
intramuscular injection
Group F : high-dose SNA02-48 + Tetanus Toxoid (Phase II)
Participants will receive a single IM gluteal injection of high-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT）
SNA02-48
intramuscular injection
Tetanus Toxoid
intramuscular injection
Group G : placebo + Tetanus Toxoid (Phase II)
Participants will receive a single IM gluteal injection of placebo and a single IM deltoid injection of Tetanus Toxoid（TT）
Placebo
intramuscular injection
Tetanus Toxoid
intramuscular injection
Group H : Human tetanus immunoglobulin(HTIG) + placebo (Phase II)
Participants will receive a single IM gluteal injection of Human tetanus immunoglobulin(HTIG) and a single IM deltoid injection of placebo
Placebo
intramuscular injection
HTIG
intramuscular injection
Group I : Human tetanus immunoglobulin(HTIG) + Tetanus Toxoid（TT） (Phase II)
Participants will receive a single IM gluteal injection of Human tetanus immunoglobulin(HTIG) and a single IM deltoid injection of Tetanus Toxoid（TT）
HTIG
intramuscular injection
Tetanus Toxoid
intramuscular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SNA02-48
intramuscular injection
Placebo
intramuscular injection
HTIG
intramuscular injection
Tetanus Toxoid
intramuscular injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants have the ability to understand and agree to sign the informed consent form；
3. Male participants with a weight of≥50.0kg; Female participants with a weight of ≥ 45.0kg and the weight of both men and women≤90 kg, 18.5 kg/m2≤BMI \< 24.0 kg/m2;
4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures from the date of signing the informed consent form until 6 months after the administration of the investigational drug, and have no plans to donate sperm or ova during this period.
Exclusion Criteria
2. Has received tetanus vaccines or vaccines containing tetanus toxoid antigen (DTP, DT, meningococcal conjugate vaccine, etc.) within the last 10 years, or has received a tetanus immunoglobulin or tetanus antitoxin within the previous 6 months;
3. Participants with positive tetanus antibody IgG test results during the screening period；
4. Participants who are known to be allergic to experimental drugs (including excipients, HTIG, and other therapeutic monoclonal antibodies), or who suffer from severe allergic diseases, may damage the safety of the participants by the judgment of the investigator;
5. Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV antibody (HIV Ab), or Treponema pallidum antibody (TP Ab);
6. Physical examinations, vital signs, electrocardiograms (ECGs), laboratory tests, or other test results during the screening or baseline period that are judged by the investigator to be abnormal and clinically significant;
7. Participants with uncontrolled chronic or severe disease history, including but not limited to cardiovascular disease, hematological system disease, hepatobiliary or renal diseases, gastrointestinal diseases, respiratory disease, malignant tumor, history of major organ transplantation, which may affect the pharmacokinetic profiles or safety evaluation of the investigational drug as determined by the investigator;
8. Autoimmune diseases or immunodeficiency disorders (including but not limited to systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), autoimmune thyroid diseases (AITD), asplenia, functional asplenia, or human immunodeficiency virus infection (HIV));
9. Participants with coagulation dysfunction that is abnormal and clinically significant as determined by the investigator (e.g., coagulation factor deficiency, platelet abnormalities);
10. Current or past history of severe neurological disorders (including but not limited to epilepsy, convulsions, or seizures) or psychiatric disorders, or a family history of psychiatric disorders;
11. Have a history of drug abuse or dependence or recreational drug use within 2 years prior to screening, or have a positive urine drug abuse screening before enrollment;
12. Participants who have received immunosuppressants or other immunomodulatory therapies (e.g., prednisone≥20 mg/day or equivalent) for≥14 days within the 6 months, cytotoxic therapy, or plan to receive such treatments during the trial period;
13. Participants who have received immune globulin or other blood products within the 6 months, or plan to receive such treatments during the trial period;
14. Participants who have donated \>400 ml of blood or experienced significant blood loss \>400 ml within 3 months prior to drug administration, or donated plasma or platelets within 1 month prior to drug administration;
15. Participants who have participated in other drug or medical device clinical trials within 3 months prior to screening, or plan to participate in other clinical trials during the trial period;
16. Participants who have smoked≥5 cigarettes per day within 3 months prior to screening;
17. Participants who have consumed \>14 alcohol units per week within 3 months prior to screening (1 alcohol unit = 14 grams of pure alcohol = 360 ml beer, 150 ml wine, or 45 ml distilled spirits/liquor);
18. Acute diseases, acute exacerbation of chronic diseases or surgical history within 4 weeks prior to screening;
19. Receipt of live attenuated vaccines within 4 weeks prior to screening or subunit/inactivated vaccines (or other vaccine types) within 7 days prior to screening;
20. Receipt of any prescription medications, over-the-counter (OTC) medications supplements, or functional vitamins within 14 days prior to screening;
21. Participants who have consumed special diets (e.g., grapefruit, etc.) or engaged in strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion within 14 days prior to screening;
22. Women in pregnancy or lactation or those with a positive pregnancy test;
23. Participants who have consumed any caffeine-containing or tea within 24 hours prior to investigational drug administration;
24. Ear temperature during the screening or baseline period is\> 37.6℃;
25. Skin lesions (including inflammation, ulcers, rashes, or scars) at the target injection site that may interfere with drug administration or observation of local reactions;
26. According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
18 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinovac Life Sciences Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-SNA02-48-1001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.